A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants

• Published in: Yonsei medical journal Vol. 48; no. 4; pp. 619 - 626
• Main Authors: Jeon, Ga Won, Koo, Soo Hyun, Lee, Jang Hoon, Hwang, Jong Hee, Kim, Sung Shin, Lee, Eun Kyung, Chang, Wook, Chang, Yun Sil, Park, Won Soon
• Format: Journal Article
• Language: English
• Published: Korea (South) Yonsei University College of Medicine 31.08.2007
• Subjects: Amphotericin B - adverse effects; Amphotericin B - therapeutic use; Candidiasis - drug therapy; Female; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Male; Original
• ISSN: 0513-5796; 1976-2437
• DOI: 10.3349/ymj.2007.48.4.619

Amphotericin B is considered the treatment of choice for systemic candidiasis, but adverse effects may limit its use. An alternative option for the treatment of candidiasis includes lipid preparations of amphotericin B. This study investigated the safety and efficacy of AmBisome, a lipid formulation of amphotericin B containing liposomal structures, for the treatment of systemic candidiasis in very low birth weight infants (VLBWI). Data from 26 VLBWI treated with AmBisome in the study group (AmBisome group) from October 2003 to July 2006 were compared with data from 20 VLBWI treated with amphotericin B as a historical control (Amphotericin group). This study was a prospective, historical control, multi-center trial. Candida spp. was isolated in 73% (19/26) of the cases for the AmBisome group and 90% (18/20) of the cases for the Amphotericin group. The fungal eradication rate and the time to eradication was 84% (16/19) and 9+/-8 days in the AmBisome group, and 89% (16/18) and 10+/-9 days in the Amphotericin group, respectively (p=0.680 vs p=0.712). The major adverse effects were lower in the AmBisome group (renal toxicity, 21% vs 55%, p=0.029; hepatotoxity, 25% vs 65%, p=0.014, AmBisome group vs Amphotericin group, respectively). There was no significant difference in mortality attributed to systemic candidiasis (12% in the AmBisome group, 10% in the Amphotericin group, p=0.868). AmBisome is effective and safe for treating systemic fungal infections in VLBWI.